Structural Motives in W.A. Mozart's Serenade No. 12 in C Minor, K. 388, First Movement

James Perone 漢陽大學校 音樂硏究所 1985 音樂論壇 Vol.2 No.-

1782년 작품인 Serenade No. 12는 Mozart가 쓴, C단조의 3작품(짧은 캐논은 제외)중의 하나로서, 제1악장에서는 반음계주의, 도약, 그리고 비대칭적인 낭송조의 악절들이 두드러지게 쓰이고 있어서, 목관을 위한 그의 실내악곡들의 대부분이 지닌 가벼운 사회성과 대조를 이룬다. 또한 이 악장에서는 두개의 주요동기, 즉 감7도 도약과 반음계적 하행선율의 동기들이 지역적에서 뿐 아니라 middleground와 background에서 또한 중요한 역할을 하는데, 본 논문에서는, 이 두 동기들의 여러층의 구조에서의 각각의 기능들이 도해식 축소법을 통해 분석 연구 되었다.

Comments on the article "Time-series comparison of COVID-19 case fatality rates across 21 countries with adjustment for multiple covariates"

Gaetano Perone 질병관리본부 2023 Osong Public Health and Research Persptectives Vol.14 No.2

Sustainable Development of Peri-urban Vegetable Production in Europe

Jean-Yves Peron,Emmanuel Geoffriau 한국원예학회 2006 한국원예학회 기타간행물 Vol.- No.-

Effect of Xylanase Supplementation on the Net Energy for Production, Performance and Gut Microflora of Broilers Fed Corn/Soy-based Diet

Nian, F.,Guo, Y.M.,Ru, Y.J.,Peron, A.,Li, F.D. Asian Australasian Association of Animal Productio 2011 Animal Bioscience Vol.24 No.9

The objective of this study was to assess the effect of xylanase on net energy for production, performance, nutrient digestion and gut microflora of broilers fed corn/soy-based diet. Eighty-four day-old male broiler chicks were allocated to two groups receiving two treatments, respectively. Each treatment had six replicate cages with seven broilers per cage. The diets were based on corn and soybean. The treatments were: i) basal diet reduced in apparent metabolizable energy (-0.63 MJ/kg compared to commercial diet specifications); ii) basal diet supplemented xylanase at 4,000 u/kg feed. The experiment used the auto-control, open circuit respiration calorimetry apparatus to examine the heat production and net energy for production. The results revealed that xylanase supplementation did not affect growth performance and diet AME value, but increased $NE_p$ value by 18.2% (p<0.05) and decreased daily heat production per $kg^{0.75}$ by 31.7% (p<0.05). There was no effect (p>0.05) of xylanase supplementation on the ileal digestibility of N and hemicelluloses, but the ileum digestibility of energy was increased by 2% by xylanase supplementation (p<0.05). Xylanase supplementation increased (p<0.05) the count of lactobacillus and bifidobacterial in the caecum.

Effect of Exogenous Xylanase Supplementation on the Performance, Net Energy and Gut Microflora of Broiler Chickens Fed Wheat-based Diets

Nian, F.,Guo, Y.M.,Ru, Y.J.,Li, F.D.,Peron, A. Asian Australasian Association of Animal Productio 2011 Animal Bioscience Vol.24 No.3

An experiment was carried out to assess the effects of xylanase supplementation on the performance, net energy and gut microflora of broilers fed a wheat-based diet. Day-old male broiler chicks were allocated to two dietary treatments. Each treatment was composed of six replicate cages of seven broilers per cage. The diets were wheat-based and offered as mash. The treatments included i) basal diet deficient in metabolizable energy; and ii) basal diet supplemented with a commercial xylanase added at 4,000 U/kg feed. Bird performance, nutrient utilization and gut microbial populations were measured. Heat production and net energy were determined using an auto-control, open circuit respiration calorimetry apparatus. Results showed that exogenous xylanase supplementation improved feed conversion efficiency (p<0.05) and increased diet AME (+4.2%; p<0.05), as well as heat production (HP), net energy for production (NEp), production of $CO_2$, and consumption of $O_2$. The respiratory quotient (RQ) was also increased (p<0.01) by the addition of xylanase. NEp value was increased by 26.1% while daily heat production per kg metabolizable body weight was decreased by 26.2% when the xylanase was added. Xylanase supplementation numerically increased the ileal digestibility of protein and energy by 3 and 6 percentage units respectively (p>0.05). The ileal digestibility of hemicellulose was significantly improved by xylanase addition (p<0.05).

Effect of Bacillus amyloliquefaciens-based Direct-fed Microbial on Performance, Nutrient Utilization, Intestinal Morphology and Cecal Microflora in Broiler Chickens

Lei, Xinjian,Piao, Xiangshu,Ru, Yingjun,Zhang, Hongyu,Peron, Alexandre,Zhang, Huifang Asian Australasian Association of Animal Productio 2015 Animal Bioscience Vol.28 No.2

The present study was conducted to evaluate the effect of the dietary supplementation of Bacillus amyloliquefaciens-based direct-fed microbial (DFM) on growth performance, nutrient utilization, intestinal morphology and cecal microflora in broiler chickens. A total of two hundred and eighty eight 1-d-old Arbor Acres male broilers were randomly allocated to one of four experimental treatments in a completely randomized design. Each treatment was fed to eight replicate cages, with nine birds per cage. Dietary treatments were composed of an antibiotic-free basal diet (control), and the basal diet supplemented with either 15 mg/kg of virginiamycin as antibiotic growth promoter (AGP), 30 mg/kg of Bacillus amyloliquefaciens-based DFM (DFM 30) or 60 mg/kg of Bacillus amyloliquefaciens-based DFM (DFM 60). Experimental diets were fed in two phases: starter (d 1 to 21) and finisher (d 22 to 42). Growth performance, nutrient utilization, morphological parameters of the small intestine and cecal microbial populations were measured at the end of the starter (d 21) and finisher (d 42) phases. During the starter phase, DFM and virginiamycin supplementation improved the feed conversion ratio (FCR; p<0.01) compared with the control group. For the finisher phase and the overall experiment (d 1 to 42) broilers fed diets with the DFM had better body weight gain (BWG) and FCR than that of control (p<0.05). Supplementation of virginiamycin and DFM significantly increased the total tract apparent digestibility of crude protein (CP), dry matter (DM) and gross energy during both starter and finisher phases (p<0.05) compared with the control group. On d 21, villus height, crypt depth and villus height to crypt depth ratio of duodenum, jejunum, and ileum were significantly increased for the birds fed with the DFM diets as compared with the control group (p<0.05). The DFM 30, DFM 60, and AGP groups decreased the Escherichia coli population in cecum at d 21 and d 42 compared with control group (p<0.01). In addition, the population of Lactobacillus was increased in DFM 30 and DFM 60 groups as compared with control and AGP groups (p<0.01). It can be concluded that Bacillus amyloliquefaciens-based DFM could be an alternative to the use of AGPs in broilers diets based on plant protein.

Effect of Bacillus amyloliquefaciens-based Direct-fed Microbial on Performance, Nutrient Utilization, Intestinal Morphology and Cecal Microflora in Broiler Chickens

Xinjian Lei,Xiangshu Piao,Yingjun Ru,Hongyu Zhang,Alexandre Peron,Huifang Zhang 아세아·태평양축산학회 2015 Animal Bioscience Vol.28 No.2

The present study was conducted to evaluate the effect of the dietary supplementation of Bacillus amyloliquefaciens-based direct-fed microbial (DFM) on growth performance, nutrient utilization, intestinal morphology and cecal microflora in broiler chickens. A total of two hundred and eighty eight 1-d-old Arbor Acres male broilers were randomly allocated to one of four experimental treatments in a completely randomized design. Each treatment was fed to eight replicate cages, with nine birds per cage. Dietary treatments were composed of an antibiotic-free basal diet (control), and the basal diet supplemented with either 15 mg/kg of virginiamycin as antibiotic growth promoter (AGP), 30 mg/kg of Bacillus amyloliquefaciens-based DFM (DFM 30) or 60 mg/kg of Bacillus amyloliquefaciens-based DFM (DFM 60). Experimental diets were fed in two phases: starter (d 1 to 21) and finisher (d 22 to 42). Growth performance, nutrient utilization, morphological parameters of the small intestine and cecal microbial populations were measured at the end of the starter (d 21) and finisher (d 42) phases. During the starter phase, DFM and virginiamycin supplementation improved the feed conversion ratio (FCR; p<0.01) compared with the control group. For the finisher phase and the overall experiment (d 1 to 42) broilers fed diets with the DFM had better body weight gain (BWG) and FCR than that of control (p<0.05). Supplementation of virginiamycin and DFM significantly increased the total tract apparent digestibility of crude protein (CP), dry matter (DM) and gross energy during both starter and finisher phases (p<0.05) compared with the control group. On d 21, villus height, crypt depth and villus height to crypt depth ratio of duodenum, jejunum, and ileum were significantly increased for the birds fed with the DFM diets as compared with the control group (p<0.05). The DFM 30, DFM 60, and AGP groups decreased the Escherichia coli population in cecum at d 21 and d 42 compared with control group (p<0.01). In addition, the population of Lactobacillus was increased in DFM 30 and DFM 60 groups as compared with control and AGP groups (p<0.01). It can be concluded that Bacillus amyloliquefaciens-based DFM could be an alternative to the use of AGPs in broilers diets based on plant protein.

Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma

Abou-Alfa, G.K.,Puig, O.,Daniele, B.,Kudo, M.,Merle, P.,Park, J.W.,Ross, P.,Peron, J.M.,Ebert, O.,Chan, S.,Poon, T.P.,Colombo, M.,Okusaka, T.,Ryoo, B.Y.,Minguez, B.,Tanaka, T.,Ohtomo, T.,Ukrainskyj, S Elsevier Science Publishers 2016 Journal of hepatology Vol.65 No.2

<P>Background & Aims: Codrituzumab, a humanized monoclonal antibody against Glypican-3 (GPC3) that is expressed in hepatocellular carcinoma (HCC), interacts with CD16/FccRIIIa and triggers antibody-dependent cytotoxicity. Codrituzumab was studied vs. placebo in a randomized phase II trial in advanced HCC patients who had failed prior systemic therapy. Methods: Patients with advanced HCC who had failed prior systemic therapy, >= 18 years, Eastern cooperative oncology group (ECOG) 0-1, Child-Pugh A were randomized 2: 1 to biweekly codrituzumab 1600 mg vs. placebo. Patients were stratified based on GPC3 immunohistochemical expression: 2+/3+, 1+, and 0. Primary endpoint was progression free survival. Secondary endpoints include overall survival (OS), tolerability, pharmacokinetics, and an exploratory endpoint in biomarkers analysis. Results: 185 patients were enrolled: 125 received codrituzumab and 60 placebo: Median age 64/63, 85/75% male, 46/42% Asian, ECOG 0 65/63%, 74/77% having vascular invasion and/or extrahepatic metastasis. 84%/70% had prior sorafenib. Drug exposure was 98.4% of planned dose, with an identical adverse events profile between the 2 groups. The median progression free survival and overall survival in the codrituzumab vs. placebo groups in months were: 2.6 vs. 1.5 (hazard ratios 0.97, p = 0.87), and 8.7 vs. 10 (hazard ratios 0.96, p = 0.82). Projected Ctrough at cycle 3 day 1 based exposure, high CD16/FccRIIIa on peripheral immune cells, and GPC3 expression in the tumor, were all associated with prolonged progression free survival and overall survival. Conclusions: Codrituzumab did not show clinical benefit in this previously treated HCC population. Whether higher codrituzumab drug exposure or the use of CD16 and GPC3 as potential biomarkers would improve outcome remain unanswered questions. Lay summary: Codrituzumab is a manufactured antibody against a liver cancer protein called glypican-3. In this clinical trial, codrituzumab was not found be effective against liver cancer. It was suggested though that a higher dose of codrituzumab or selecting patients with high level of glypican-3 or its mediator CD16 might improve outcome. (C) 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.</P>